Compare Adaptive Biotechnologies Corp (ADPT) vs PayPal Holdings, Inc. (PYPL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs PayPal Holdings, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while PayPal Holdings, Inc. trades at $44.46 (market cap $40.27B). The key difference: PayPal Holdings, Inc. is far larger — about 12.1× Adaptive Biotechnologies Corp's market cap, and PayPal Holdings, Inc. pays a 1.23% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | PYPL | |
|---|---|---|
Market Cap | $3.33B | $40.27B |
Sector | Health | Financials |
52-Week High | $22.37 | $78.22 |
52-Week Low | $10.24 | $39.08 |
Enterprise Value | $3.19B | $40.34B |
Dividend Yield | — | 1.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
PayPal trades at $45.65, up 0.4% with a bullish technical outlook. The stock appears undervalued with a P/E of 8.46 and strong profitability metrics including 15% net income margin and 25.12% ROE. Recent earnings beat expectations in Q1 2026, and the company maintains robust cash flow generation of $6.4B from operations. Analyst consensus is mixed with 37% buy ratings but a $49 price target suggesting 7% upside potential.
PayPal presents a value opportunity with attractive valuation multiples and solid fundamentals, though growth moderation and competitive pressures remain concerns. The stock's technical strength and dividend initiation provide support, while legal scrutiny and execution risks warrant monitoring. Upside appears limited near-term but long-term prospects remain favorable if management delivers on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About PayPal Holdings, Inc.
PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants. The Company offers online payment solutions. PayPal Holdings serves customers worldwide.
Read more on PYPL →
